Analysis of cumulative live birth rate outcomes of four ovarian stimulation protocols in Poseidon groups 3/4 patients with adenomyosis.

Purpose

To compare the effects of the gonadotrophin-releasing hormone (GnRH) agonist protocol, GnRH antagonist protocol, progestin-primed ovarian stimulation (PPOS) protocol, and mild stimulation/natural cycle protocol on the cumulative live birth rate (CLBR) in patients with adenomyosis and Poseidon group 3/4.

Methods

A total of 1090 patients diagnosed with adenomyosis and Poseidon groups 3/4 group who underwent in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) from January 2013 to December 2020 were included. Demographic characteristics, laboratory indicators, and clinical outcomes of the four ovarian stimulation protocols were compared. The primary outcome was the CLBR, with binary logistic regression analysis used to explore the factors influencing CLBR.

Results

Among the patients with adenomyosis and Poseidon groups 3/4, the CLBR in GnRH agonist protocol group was higher than that in PPOS protocol group (45.78% vs. 22.33%, P = 0.005). Binary logistic regression analysis revealed that GnRH agonist protocol had a higher CLBR compared to PPOS protocol (adjusted odds ratio (aOR) 3.26, 95% confidence interval (CI): 1.56-6.83, P = 0.002), while no significant differences were found when comparing PPOS protocol with GnRH antagonist protocol (P = 0.093) and mild stimulation/natural cycle protocol (P = 0.125). In the < 35 years subgroup, the CLBR of GnRH agonist protocol was significantly higher (55.26% vs. 33.82%; P = 0.032), which wasn't observed in elder subgroups (P > 0.05).

Conclusion

For patients with both adenomyosis and Poseidon groups 3/4, GnRH agonist protocol showed a higher CLBR, especially in patients < 35 years (Poseidon group 3).

References:

• Bourdon M, et al. Adenomyosis: an update regarding its diagnosis and clinical features. J Gynecol Obstet Hum Reprod. 2021;50(10):102228.
• Puente JM, et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol. 2016;14(1):60.
• Abu Hashim H, et al. The prevalence of adenomyosis in an infertile population: a cross-sectional study. Reprod Biomed Online. 2020;40(6):842–50.
• Nirgianakis K, et al. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a systematic review and meta-analysis. Reprod Biomed Online. 2021;42(1):185–206.
• Lan J, et al. Ultra-long GnRH agonist protocol during IVF/ICSI improves pregnancy outcomes in women with adenomyosis: a retrospective cohort study. Front Endocrinol (Lausanne). 2021;12:609771.